A R.I. biotech has gained FDA approval for its eye insert that treats MacTel, a rare neurodegenerative disease.

The JV will leverage the dual-arm robot Maholo, developed by Yaskawa subsidiary the Robotic Biology Institute.

Research by UMass Chan Medical School scientists Sharon Cantor, PhD, and Jenna M. Whalen, PhD, poses a new explanation for how cancer-fighting drugs attack and destroy BRCA1 and BRCA2 tumor cells.

Metabolic cell death represents a rapidly evolving and intricate field within cancer research. Recent studies have elucidated ...

Stem cell therapy is witnessing significant traction in the Asia Pacific region, with notable applications in orthopedics, neurology, cardiology, and immune modulation. Exosome research, particularly ...

With increasing biomarker-driven cancer treatments, TEPMETKO benefits from growing adoption in precision oncology. Competition from other MET inhibitors like TABRECTA (capmatinib) exists, but ...

DelveInsight's "TEPMETKO Market Size, Forecast, and Market Insight Report" highlights the details around TEPMETKO, a kinase ...

As an expert explained in an interview with CURE, we may be in the midst of a “new era” for small cell lung cancer research.

Limula has unveiled LimONE, a cell therapy manufacturing solution that automates complex and fragmented processes into a ...

The agreement—powered by YASKAWA's Maholo robot—aims to address challenges in production and commercialization while offering ...

Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.

The US Food and Drug Administration (FDA) has approved revakinagene taroretcel-lwey (ENCELTO) from Neurotech Pharmaceuticals ...